Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy.

Shingo ToyodaWataru FukuokayaKeiichiro MoriTatsushi KawadaSatoshi KatayamaShingo NishimuraRyoichi MaenosonoTakuya TsujinoTakahiro AdachiYosuke HirasawaMasanobu SarutaKazumasa KomuraTakuhisa NukayaTakafumi YanagisawaKiyoshi Takahara Takeshi HashimotoHaruhito AzumaYoshio OhnoRyoichi ShirokiMotoo ArakiTakahiro KimuraKazutoshi Fujitanull null

Published in: Japanese journal of clinical oncology (2024)

There was no significant difference in OS or PFS between IO-IO and IO-TKI combination therapy as first-line treatment for patients with nccRCC. Liver metastasis is a poor prognostic factor for such patients.

Keyphrases

prognostic factors
combination therapy
renal cell carcinoma
squamous cell carcinoma
small cell lung cancer
single cell
palliative care
end stage renal disease
newly diagnosed
chronic kidney disease
tyrosine kinase
bone marrow
mesenchymal stem cells
epidermal growth factor receptor
patient reported outcomes